PD-L1 aAPC Cell IO星空体育官方网站首页-星空体育官方网站登录入口

產品搜索

聯係人：蔣經理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區緯地路9號
Email： zhangxiangwen@cobioer.com

CBP74164
I. Background
The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.

II. Introduction
Expressed gene:	PDL1
Stability:	32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Freeze Medium:	90% FBS+10% DMSO
Culture Medium:	RPMI-1640+10%FBS+1ug/ml puromycin+200ug/ml hygromycin
Mycoplasma Testing:	Negative
Storage:	Liquid nitrogen
Application(s):	Functional(Report Gene) Assay

III. Representative Data
Figure 1. Dose Response of Blocking Antibodies in PD-1/OX40 Dual Effector Reporter Cells (C22) With PD-L1 aAPC Cells.